Key result
Heart-type fatty acid-binding protein is an early biomarker of myocardial injury that complements troponins in ruling out acute coronary syndromes and risk stratifying other cardiac conditions.
Why the study?
Cardiac troponin kinetics necessitate prolonged ED observation or admission for ACS diagnosis and rule-out, highlighting the need to examine earlier markers like H-FABP.
Does H-FABP measurement improve early diagnosis and risk stratification in patients with chest pain or myocardial injury compared to standard troponins?
Does H-FABP measurement improve early diagnosis and risk stratification in patients with chest pain or myocardial injury compared to standard troponins?
Answers are grounded in this paper and cite their sources.
H-FABP is a rapidly released biomarker that complements troponins for early diagnosis of ACS and risk stratification in heart failure and pulmonary embolism.
Cardiac troponins (cTn) are currently the standard of care for the diagnosis of acute coronary syndromes (ACS) in patients presenting to the emergency department (ED) with chest pain (CP). However, their plasma kinetics necessitate a prolonged ED stay or overnight hospital admission, especially in those presenting early after CP onset. Moreover, ruling out ACS in low-risk patients requires prolonged ED observation or overnight hospital admission to allow serial measurements of c-Tn, adding cost. Heart-type fatty acid-binding protein (H-FABP) is a novel marker of myocardial injury with putative advantages over cTn. Being present in abundance in the myocellular cytoplasm, it is released rapidly (<1 h) after the onset of myocardial injury and could potentially play an important role in both earlier diagnosis of high-risk patients presenting early after CP onset, as well as in risk-stratifying low-risk patients rapidly. Like cTn, H-FABP also has a potential role as a prognostic marker in other conditions where the myocardial injury occurs, such as acute congestive heart failure (CHF) and acute pulmonary embolism (PE). This review provides an overview of the evidence examining the role of H-FABP in early diagnosis and risk stratification of patients with CP and in non-ACS conditions associated with myocardial injury. Key messages Heart-type fatty acid-binding protein is a biomarker that is elevated early in myocardial injury The routine use in the emergency department complements the use of troponins in ruling out acute coronary syndromes in patients presenting early with chest pain It also is useful in risk stratifying patients with other conditions such as heart failure and acute pulmonary embolism.
No takes yet. Share an insight, caveat, or question.
Goel et al. (2020) conducted a review in Acute coronary syndromes, chest pain, heart failure, acute pulmonary embolism. Heart-type fatty acid-binding protein (H-FABP) vs. Cardiac troponins (cTn) was evaluated. Heart-type fatty acid-binding protein is an early biomarker of myocardial injury that complements troponins in ruling out acute coronary syndromes and risk stratifying other cardiac conditions.
Synapse has enriched 10 related papers. Consider them for comparative context: